Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, November 7, 2026

Back to the front page

From X

@kevin__mak 3 clicks

Kevin Mak on X

$ABVX Interesting data coming from S&P Markit* (daily short interest based on institutional lending data). Looks like someone established a large position over the past 10 days or so, about 2mm shares or $200M. Given people generally don't like to have single name short exposure over 1-2% of their book (often people size shorts as like ~50 bps), this would be part of a really big book or a really big basket trade. Given the current ABVX-specific situation, it feels weird to be directly betting on the stock falling further from these levels, without any known catalysts around. My best guess is this is part of a "short France" basket trade. But I also can't find any other items of the basket with large changes in short interest to corroborate. Retail Fintwit crowding (correlation with other popular bio names) is likely having an effect as well. Plus rates. Plus biotech degrossing. What I ruled out was a world where this could/would be frontrunning ahead of a possible liquidation (There's a fund with a large ABVX position that took a huge loss on LQDA), but the timing on that is off. In fact pretty much the whole short position was established prior to LQDA crashing. My observation is that the list of items above, plausibly causing weakness in the stock, largely has nothing to do with A) Does the drug work, B) Will the drug sell well. That's what I like about situations like this. ABVX is a large position for us, we've spent a long time recently double/triple checking our fundamental views on the stock and still strongly believe that their key drug, Obefazimod, will be successful even without an acquisition. Hope to have a detailed write-up about that at some point. *I find Markit data to be the most reliable among 3rd party short data, but there are still data anomalies for various reasons. Disclosure: Creek Drive and its affiliated funds holds a long position in ABVX. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.
@StableBread

Fajasy on X

Read skeptically, Nubeva Technologies $NBVAF (TSXV: $NBVA) is a shrinking software company living off its cash, with an AI decryptor builder that keeps slipping and a license customer that may not have renewed. Read another way, Nubeva is being prepared for a buyer. Here’s what supports the second read: → In March 2024, Netskope $NTSK, now a ~$7.6B company, bought Nubeva’s TLS (web-traffic decryption) technology and five patents for $1M. Greig Bannister, the CTO who co-invented the key-capture patents, followed the technology to Netskope. → In an August 2024 video, CEO Randy Chou said “partnering and M&A groups” from companies worth $20-30B had reached out after the July 2024 CrowdStrike $CRWD outage. → Chou wants all four AI patents granted before any partnership or sale, and two are still pending. → The FY2026 MD&A says Nubeva is “selectively engaging with lighthouse accounts,” meaning “large, high-profile organizations that serve as validation points for the technology,” to make its offering “more attractive for either future expansion or strategic partnership/M&A.” In a June 2025 video, Chou said lighthouse accounts “matter 100%” in a partnership or M&A talk. → Sales and marketing spend was $14,951 for all of FY2026, with $2.49M of cash on hand. In the same June 2025 video, Chou said Nubeva is “really not marketing” until “the patents and everything else comes in.” → The most recent investor deck is from July 2023, and since then Nubeva has communicated mostly through filings, press releases, and the occasional YouTube interview. In other words, it isn’t pitching investors either, which fits a company waiting on a buyer. A longtime investor I spoke with described Chou as reluctant to spend money, PR included, and called a sale to a larger security company the clear end goal. I’d add that Chou, who makes the call, also owns a quarter of the company.
@BrokenMoats 2 clicks

Broken Moats on X

Secular theme of increasing competition in the coffee space, no issue taking a position against SBUX which still carries a premium valuation largely on that premise. My flip side to that, is why also be long Dutch $BROS? Trades worked against you for almost the same reasons - intensifying competition from direct copy cat 7 Brew. But there are many regional players that are aggressively scaling - Summermoon, Foxtail, Lala land, Merrit, etc and those are the ones just geographically close to me but it's a countrywide phenomenon. Turns out yes coffee is habitual and generates good cash returns, but barriers to entry are low. The bidding war for the Salads real estate was insane, and shows how deep pocketed 7 Brew is in their expansion, and being PE backed and not public means they might be less disciplined...... So why Bros? There might still be potential there, the model is efficient and a cult service culture, but even at current levels I find the valuation difficult to digest not to mention overhangs from GLP1s, affordability/gas prices

Investor Letters

All letters

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

VSH $3.6B
Cestrian Capital Research 3 clicks

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

MDA $4.2B
Aurelion Research 4 clicks
AAP · long

Advance Auto Parts INC

Advance Auto Parts, AAP, is presented as a long idea following prior write-ups at $48.81 per share in January 2025.

AAP $2.9B
Value Investors Club 1 click

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

CURB $3.6B
Real Assets, Real Value 5 clicks

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3…

STVN $3.6B
Best Anchor Stocks 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 277

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.